Methods and compositions for the prevention and treatment of disease
The present technology is directed to compositions and methods for preventing, ameliorating, or reducing the severity of one or more signs, or symptoms associated with a reduction of function, decreased expression level of, and/or deficiency in one or more of COL4A3, COL4A4 and COL4A5 genes. Also disclosed herein are methods of preventing or treating Alport Syndrome in a mammalian subject, reducing risk factors associated with Alport Syndrome, and/or reducing the likelihood or severity of Alport Syndrome. The methods comprise administering to the subject an effective amount of an aromatic-cationic peptide.
1. A method for treating Alport Syndrome in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of the peptide D-Arg-2′,6′-Dmt-Lys-Phe-NH 2 or a pharmaceutically acceptable salt thereof.
2. The method of claim 1 , wherein the subject displays aberrant protein levels and/or function of one or more of ADAM8, fibronectin, myosin 10, MMP-2, MMP-9, and podocin compared to a normal control subject, and wherein peptide treatment restores levels and/or function of said proteins.
3. The method of claim 1 , wherein the subject has been diagnosed as having Alport Syndrome, wherein the signs or symptoms of Alport Syndrome comprise one or more of hematuria, proteinuria, cylindruria, leukocyturia, hypertension, edema, microalbuminuria, declining glomerular filtration rate, interstitial fibrosis, interstitial inflammation, tubular damage, GBM ultrastructural abnormalities, nephrotic syndrome, glomerulonephritis, end-stage kidney disease, chronic anemia, macrothrombocytopenia, osteodystrophy, sensorineural deafness, anterior lenticonus, dot-and-fleck retinopathy, posterior polymorphous corneal dystrophy, recurrent corneal erosion, temporal macular thinning, cataracts, lacrimation, photophobia, vision loss, keratoconus, and leiomyomatosis.
4. The method of claim 1 , wherein the peptide is administered orally, topically, intranasally, systemically, intravenously, subcutaneously, intraperitoneally, intradermally, intraocularly, iontophoretically, transmucosally, or intramuscularly.
5. The method of claim 1 , further comprising separately, sequentially or simultaneously administering one or more additional therapeutic agents to the subject wherein the one or more additional therapeutic agents are selected from the group consisting of: angiotensin II converting enzyme inhibitors (ACE inhibitors), angiotensin II receptor blockers (ARBs), HMG-CoA reductase inhibitors, aldosterone inhibitors, aliskiren, calcineurin inhibitors, endothelin receptor antagonists, sulodexide, vasopeptidase inhibitors, anti-transforming growth factor-β1 antibody, chemokine receptor 1 blockers, bone morphogenetic protein-7, PPARy agonists, and BAY-12-9566.
6. The method of claim 5 , wherein the one or more additional therapeutic agents are selected from the group consisting of cyclosporine A, tacrolimus, sitaxentan, ambrisentan, atrasentan, BQ-123, zibotentan, bosentan, macitentan, tezosentan, BQ-788, A192621, AVE7688, rosiglitazone, pioglitazone, MRL24, Fmoc-L-Leu, SR1664, SR1824, GW0072, MCC555, CLX-0921, PAT5A, L-764406, nTZDpa, 2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid (CDDO), and ragaglitazar, O-arylmandelic acids.
7. The method of claim 5 , wherein the one or more additional therapeutic agents are selected from the group consisting of O-arylmandelic acids and non-steroidal anti-inflammatory drugs (NSAIDs).
8. The method of claim 1 , wherein the pharmaceutically acceptable salt comprises acetate, tartrate, or trifluoroacetate salt.
9. The method of claim 1 , wherein peptide treatment results in elevated Mfn1 expression and/or function compared to an untreated Alport Syndrome subject.